IMC-C103C Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This IMC-C103C Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether IMC-C103C can convert its Fusion protein profile and CD3 x MAGEA4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | IMC-C103C (query alias: IMC-C103C) |
|---|---|
| Modality / target | Fusion protein; CD3 x MAGEA4; CD3 inhibitors, MAGEA4 inhibitors, Gene transference |
| Highest global status | Phase 2 |
| Originator | Immunocore Ltd. |
| Active developers | Immunocore Ltd. |
The MCP disease footprint includes Esophageal Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT03973333 | Phase 1/2 | Withdrawn | 0 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
157P - Phase 1 expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma
Phase 1; n=28; evaluation: Positive. Reported fields: TRAE = Most common related AEs were pyrexia (68%), chills (52%), and CRS (45%), the vast majority were Grade 1/2. ; TRAE = Most common related AEs were pyrexia (68%), chills (52%), and CRS (45%), the vast majority were Grade 1/2.
91P - Phase 1 dose escalation of IMC-C103C, a CD3_MAGE-A4 T cell receptor (TCR) bispecific protein
Phase 1; n=42; evaluation: Positive. Reported fields: AE(grade 3) = reversible neutropenia (19%)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
IMC-C103C addresses Esophageal Carcinoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2013-06-27 | Immunocore and Genentech enter strategic alliance to develop ImmTACs for multiple cancer targets | Preclinical | US$100.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Use of Anti-CD3 antibody for selectively depleting activated t cells”. The milestone feed surfaced a patent-application signal described as “Markers for use in methods for treating cancers with antibody drug conjugates (ADC)”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-11. Counts and status fields may change as source records update.
